搜索医生

Harry H. Yoon, M.D.

  1. Oncologist
预约门诊

出版物

  1. Hallemeier CL, Merrell KW, Neben-Wittich MA, Jethwa KR, Yoon HH, Pitot HC, Blackmon S, Shen KR, Tryggestad EJ, Giffey B, Kazemba BD, Viehman JK, Harmsen WS, Haddock MG. A Prospective Pilot Study of Pencil Beam Scanning Proton Radiation Therapy as a Component of Trimodality Therapy for Esophageal Cancer. Adv Radiat Oncol. 2024 Aug; 9 (8):101547 Epub 2024 June 06
    View PubMed
  2. Jazieh K, Yoon H, Zhu M. Advances in Immunotherapy in Esophagogastric Cancer. Hematol Oncol Clin North Am. 2024 Jun; 38 (3):599-616 Epub 2024 Mar 15
    View PubMed
  3. Xu J, Kato K, Raymond E, Hubner RA, Shu Y, Pan Y, Park SR, Ping L, Jiang Y, Zhang J, Wu X, Yao Y, Shen L, Kojima T, Gotovkin E, Ishihara R, Wyrwicz L, Van Cutsem E, Jimenez-Fonseca P, Lin CY, Wang L, Shi J, Li L, Yoon HH. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2023 May; 24 (5):483-495 Epub 2023 Apr 17
    View PubMed
  4. Zhu M, Zhang H, Pedersen KS, Foster NR, Jaszewski BL, Liu X, Hirdler JB, An Z, Bekaii-Saab TS, Halfdanarson TR, Boland PM, Yan Y, Hubbard JH, Ma WW, Yoon HH, Revzin A, Fernandez-Zapico ME, Overman MJ, McWilliams RR, Dong H. Understanding Suboptimal Response to Immune Checkpoint Inhibitors. Adv Biol (Weinh). 2023 Apr; 7 (4):e2101319 Epub 2022 Mar 27
    View PubMed
  5. Ajani JA, D'Amico TA, Bentrem DJ, Cooke D, Corvera C, Das P, Enzinger PC, Enzler T, Farjah F, Gerdes H, Gibson M, Grierson P, Hofstetter WL, Ilson DH, Jalal S, Keswani RN, Kim S, Kleinberg LR, Klempner S, Lacy J, Licciardi F, Ly QP, Matkowskyj KA, McNamara M, Miller A, Mukherjee S, Mulcahy MF, Outlaw D, Perry KA, Pimiento J, Poultsides GA, Reznik S, Roses RE, Strong VE, Su S, Wang HL, Wiesner G, Willett CG, Yakoub D, Yoon H, McMillian NR, Pluchino LA. Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023 Apr; 21 (4):393-422
    View PubMed
  6. Zhu M, Ganesan C, Flanagan S, Yoon HH. Life-threatening "hyper-progression" on immunotherapy revealed as pseudo-progression in DNA mismatch repair deficiency: a case report. J Gastrointest Oncol. 2023 Feb 28; 14 (1):435-441 Epub 2023 Feb 14
    View PubMed
  7. Yoon HH, Shi Q, Ajani JA. Tissue-Based PD-L1 Expression Is the Strongest Predictor of Overall Survival Benefit From ICI in Advanced Gastroesophageal Cancer-Reply. JAMA Oncol 2023 Feb 1; 9 (2):280-281
    View PubMed
  8. Kowalchuk RO, Spears GM, Morris LK, Owen D, Yoon HH, Jethwa K, Chuong MD, Ferris MJ, Haddock MG, Hallemeier CL, Wigle D, Lin SH, Merrell KW. Risk stratification of postoperative cardiopulmonary toxicity after trimodality therapy for esophageal cancer. Front Oncol. 2023; 13:1081024 Epub 2023 Feb 09
    View PubMed
  9. Wang-Gillam A, Lim KH, McWilliams R, Suresh R, Lockhart AC, Brown A, Breden M, Belle JI, Herndon J, Bogner SJ, Pedersen K, Tan B, Boice N, Acharya A, Abdiannia M, Gao F, Yoon HH, Zhu M, Trikalinos NA, Ratner L, Aranha O, Hawkins WG, Herzog BH, DeNardo DG. Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study. Clin Cancer Res. 2022 Dec 15; 28 (24):5254-5262
    View PubMed
  10. Yoon HH, Jin Z, Kour O, Kankeu Fonkoua LA, Shitara K, Gibson MK, Prokop LJ, Moehler M, Kang YK, Shi Q, Ajani JA. Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer: Systematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical Trials. JAMA Oncol. 2022 Oct 1; 8 (10):1456-1465
    View PubMed
  11. Catenacci DVT, Kang YK, Yoon HH, Shim BY, Kim ST, Oh DY, Spira AI, Ulahannan SV, Avery EJ, Boland PM, Chao J, Chung HC, Gardner F, Klempner SJ, Lee KW, Oh SC, Peguero J, Sonbol MB, Shen L, Moehler M, Sun J, Li D, Rosales MK, Park H. Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A. ESMO Open. 2022 Oct; 7 (5):100563 Epub 2022 Aug 24
    View PubMed
  12. Yoon HH, Dong H, Shi Q. Impact of PD-1 Blockade in Nonresponders: Pitfalls and Promise. Clin Cancer Res 2022 Aug 2; 28 (15):3173-3175
    View PubMed
  13. Zhu M, Chen C, Foster NR, Hartley C, Mounajjed T, Salomao MA, Fruth BF, Beamer SE, Kim Y, Harrington SM, Pitot HC, Sanhueza CT, Feng Y, Herrmann J, McWilliams RR, Lucien F, Huang BQ, Ma WW, Bekaii-Saab TS, Dong H, Wigle D, Ahn DH, Hallemeier CL, Blackmon S, Yoon HH. Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction. Clin Cancer Res. 2022 Jul 15; 28 (14):3021-3031
    View PubMed
  14. Catenacci DVT, Chung HC, Shen L, Moehler M, Yoon HH, Rosales MK, Kang YK. Safety and efficacy of HER2 blockade by trastuzumab-based chemotherapy-containing combination strategies in HER2+ gastroesophageal adenocarcinoma. ESMO Open. 2022 Feb; 7 (1):100360 Epub 2021 Dec 29
    View PubMed
  15. Ajani JA, D'Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, Das P, Enzinger PC, Enzler T, Fanta P, Farjah F, Gerdes H, Gibson MK, Hochwald S, Hofstetter WL, Ilson DH, Keswani RN, Kim S, Kleinberg LR, Klempner SJ, Lacy J, Ly QP, Matkowskyj KA, McNamara M, Mulcahy MF, Outlaw D, Park H, Perry KA, Pimiento J, Poultsides GA, Reznik S, Roses RE, Strong VE, Su S, Wang HL, Wiesner G, Willett CG, Yakoub D, Yoon H, McMillian N, Pluchino LA. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 Feb; 20 (2):167-192
    View PubMed
  16. Yoon HH. Ramucirumab plus paclitaxel for gastric cancer in China. Lancet Gastroenterol Hepatol. 2021 Dec; 6 (12):975-976 Epub 2021 Oct 07
    View PubMed
  17. Kankeu Fonkoua LA, Chakrabarti S, Sonbol MB, Kasi PM, Starr JS, Liu AJ, Nevala WK, Maus RL, Bois MC, Pitot HC, Chandrasekharan C, Ross HJ, Wu TT, Graham RP, Villasboas JC, Weiss M, Foster NR, Markovic SN, Dong H, Yoon HH. Outcomes on anti-VEGFR-2/paclitaxel treatment after progression on immune checkpoint inhibition in patients with metastatic gastroesophageal adenocarcinoma. Int J Cancer. 2021 Jul 15; 149 (2):378-386 Epub 2021 Mar 26
    View PubMed
  18. Jin Z, Shen J, Wang C, Chen D, Zhang B, Zhang J, Ajani JA, Bennouna J, Chao J, Yoon HH, Zhu H, Ruan Y, Zhu C, Xu A. Narrative review of pembrolizumab for the treatment of esophageal cancer: evidence and outlook. Ann Transl Med. 2021 Jul; 9 (14):1189
    View PubMed
  19. Chao J, Fuchs CS, Shitara K, Tabernero J, Muro K, Van Cutsem E, Bang YJ, De Vita F, Landers G, Yen CJ, Chau I, Elme A, Lee J, Ozguroglu M, Catenacci D, Yoon HH, Chen E, Adelberg D, Shih CS, Shah S, Bhagia P, Wainberg ZA. Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. JAMA Oncol. 2021 Jun 1; 7 (6):895-902
    View PubMed
  20. Yoon HH, Ou FS, Soori GS, Shi Q, Wigle DA, Sticca RP, Miller RC, Leenstra JL, Peller PJ, Ginos B, Heying E, Wu TT, Drevyanko TF, Ko S, Mattar BI, Nikcevich DA, Behrens RJ, Khalil MF, Kim GP, Alberts SR. Induction versus no induction chemotherapy before neoadjuvant chemoradiotherapy and surgery in oesophageal adenocarcinoma: a multicentre randomised phase II trial (NCCTG N0849 [Alliance]). Eur J Cancer. 2021 Jun; 150:214-223 Epub 2021 Apr 29
    View PubMed
  21. Catenacci DV, Rosales M, Chung HC, H Yoon H, Shen L, Moehler M, Kang YK. MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma. Future Oncol. 2021 Apr; 17 (10):1155-1164 Epub 2020 Dec 02
    View PubMed
  22. Zhu M, Sonbol MB, Yoon HH. Trifluridine/tipiracil plus ramucirumab in gastric cancer. Lancet Gastroenterol Hepatol 2021 Mar; 6 (3):154-155 Epub 2021 Jan 26
    View PubMed
  23. Yoon HH. Progressive, locally advanced unresectable, and metastatic esophageal and gastric cancer: Approach to later lines of systemic therapy UpToDate [Internet] (updated continuously and peer-reviewed, Yoon HH has been coauthor since 2012). Most Recent Update 2021. 2021.
  24. Childs DS, Yoon HH, Eiring RA, Jin Z, Jochum JA, Pitot HC, Jatoi A. Falls: descriptive rates and circumstances in age-unspecified patients with locally advanced esophageal cancer. Support Care Cancer. 2021 Feb; 29 (2):733-739 Epub 2020 May 24
    View PubMed
  25. Francini E, Ou FS, Lazzi S, Petrioli R, Multari AG, Pesola G, Messuti L, Colombo E, Livellara V, Bazzurri S, Cherri S, Miano ST, Wolfe EG, Alberts SR, Hubbard JM, Yoon HH, Francini G. The prognostic value of CD3+ tumor-infiltrating lymphocytes for stage II colon cancer according to use of adjuvant chemotherapy: A large single-institution cohort study. Transl Oncol. 2021 Feb; 14 (2):100973 Epub 2020 Dec 15
    View PubMed
  26. Yoon HH. Initial systemic therapy for locally advanced unresectable and metastatic esophageal and gastric cancer UpToDate [Internet] (updated continuously and peer-reviewed, Yoon HH has been coauthor since 2012). Most Recent Update 2021.
  27. Walden D, Sonbol MB, Buckner Petty S, Yoon HH, Borad M, Bekaii-Saab TS, Ahn DH. Maintenance Therapy in First-Line Gastric and Gastroesophageal Junction Adenocarcinoma: A Retrospective Analysis. Front Oncol. 2021; 11:641044 Epub 2021 Sept 10
    View PubMed
  28. Kankeu Fonkoua LA, Yoon HH. Rapidly Evolving Treatment Landscape for Metastatic Esophagogastric Carcinoma: Review of Recent Data. Onco Targets Ther. 2021; 14:4361-4381 Epub 2021 Aug 05
    View PubMed
  29. Deng W, Jethwa KR, Gonuguntla K, Liao Z, Yoon HH, Murphy MB, Haddock MG, Hallemeier CL, Lin SH. Multi-institutional Evaluation of Curative Intent Chemoradiotherapy for Patients With Clinical T1N0 Esophageal Adenocarcinoma. Adv Radiat Oncol. 2020 Sep-Oct; 5 (5):951-958 Epub 2020 Apr 27
    View PubMed
  30. Garant A, Whitaker TJ, Spears GM, Routman DM, Harmsen WS, Wilhite TJ, Ashman JB, Sio TT, Rule WG, Neben Wittich MA, Martenson JA, Tryggestad EJ, Yoon HH, Blackmon S, Merrell KW, Haddock MG, Hallemeier CL. A Comparison of Patient-Reported Health-Related Quality of Life During Proton Versus Photon Chemoradiation Therapy for Esophageal Cancer. Pract Radiat Oncol. 2019 Nov; 9 (6):410-417 Epub 2019 July 13
    View PubMed
  31. Bang YJ, Kang YK, Catenacci DV, Muro K, Fuchs CS, Geva R, Hara H, Golan T, Garrido M, Jalal SI, Borg C, Doi T, Yoon HH, Savage MJ, Wang J, Dalal RP, Shah S, Wainberg ZA, Chung HC. Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. Gastric Cancer. 2019 Jul; 22 (4):828-837 Epub 2019 Mar 25
    View PubMed
  32. Jin Z, Holubek M, Sukov WR, Sattler CA, Wiktor AE, Jenkins RB, Wu TT, Yoon HH. Identification of Adenosquamous Carcinoma as a Rare Aggressive HER2-negative Subgroup of Esophageal/Gastroesophageal Junction Adenocarcinoma. Am J Clin Oncol. 2019 Feb; 42 (2):190-195
    View PubMed
  33. Routman DM, Garant A, Lester SC, Day CN, Harmsen WS, Sanheuza CT, Yoon HH, Neben-Wittich MA, Martenson JA, Haddock MG, Hallemeier CL, Merrell KW. A Comparison of Grade 4 Lymphopenia With Proton Versus Photon Radiation Therapy for Esophageal Cancer. Adv Radiat Oncol. 2019 Jan-Mar; 4 (1):63-69 Epub 2019 Jan 17
    View PubMed
  34. Yoon HH, Shi Q, Heying EN, Muranyi A, Bredno J, Ough F, Djalilvand A, Clements J, Bowermaster R, Liu WW, Barnes M, Alberts SR, Shanmugam K, Sinicrope FA. Intertumoral Heterogeneity of CD3(+) and CD8(+) T-Cell Densities in the Microenvironment of DNA Mismatch-Repair-Deficient Colon Cancers: Implications for Prognosis. Clin Cancer Res. 2019 Jan 1; 25 (1):125-133 Epub 2018 Oct 09
    View PubMed
  35. Yoon H, Karapetyan L, Choudhary A, Kosozi R, Bali GS, Zaidi AH, Atasoy A, Forastiere AA, Gibson MK. Phase II Study of Irinotecan Plus Panitumumab as Second-Line Therapy for Patients with Advanced Esophageal Adenocarcinoma. Oncologist. 2018 Sep; 23 (9):1004-e102 Epub 2018 May 16
    View PubMed
  36. Chakrabarti S, Dong H, Paripati HR, Ross HJ, Yoon HH. First Report of Dramatic Tumor Responses with Ramucirumab and Paclitaxel After Progression on Pembrolizumab in Two Cases of Metastatic Gastroesophageal Adenocarcinoma. Oncologist. 2018 Jul; 23 (7):840-843 Epub 2018 Apr 19
    View PubMed
  37. Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, Garrido M, Golan T, Mandala M, Wainberg ZA, Catenacci DV, Ohtsu A, Shitara K, Geva R, Bleeker J, Ko AH, Ku G, Philip P, Enzinger PC, Bang YJ, Levitan D, Wang J, Rosales M, Dalal RP, Yoon HH. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol. 2018 May 10; 4 (5):e180013
    View PubMed
  38. Arnold D, Fuchs CS, Tabernero J, Ohtsu A, Zhu AX, Garon EB, Mackey JR, Paz-Ares L, Baron AD, Okusaka T, Yoshino T, Yoon HH, Das M, Ferry D, Zhang Y, Lin Y, Binder P, Sashegyi A, Chau I. Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab. Ann Oncol. 2017 Dec 1; 28 (12):2932-2942
    View PubMed
  39. Yoon HH. Novel treatment strategies in carcinoma of unknown primary. Ann Oncol. 2017 Oct; 28 Suppl 9:ix25
    View PubMed
  40. Jin Z, Yoon HH. Antiangiogenic Therapy in Gastroesophageal Cancer. Hematol Oncol Clin North Am. 2017 Jun; 31 (3):499-510 Epub 2017 Mar 22
    View PubMed
  41. Yoon HH, Bendell JC, Wainberg ZA. Consideration of an association between performance status and ramucirumab efficacy. Ann Oncol 2017 Apr 1; 28 (4):902-903
    View PubMed
  42. Childs DS, Jacobson AC, Mitchell JL, Hubbard JM, Yoon HH, Finnes H, Grothey A, Jatoi A. Prescriber adherence to antiemetic guidelines with the new agent trifuridine-tipiracil Journal of Community and Supportive Oncology. 2017; 15: (3)e142-6.
  43. Yoon HH, Bendell JC, Braiteh FS, Firdaus I, Philip PA, Cohn AL, Lewis N, Anderson DM, Arrowsmith E, Schwartz JD, Gao L, Hsu Y, Xu Y, Ferry D, Alberts SR, Wainberg ZA. Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial. Ann Oncol. 2016 Dec; 27 (12):2196-2203 Epub 2016 Oct 20
    View PubMed
  44. Jin Z, Yoon HH. The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1. J Gastrointest Oncol. 2016 Oct; 7 (5):771-788
    View PubMed
  45. Yoon HH, Lewis MA, Foster NR, Sukov WR, Khan M, Sattler CA, Wiktor AE, Wu TT, Jenkins RB, Sinicrope FA. Central nervous system relapse in patients with untreated HER2-positive esophageal or gastroesophageal junction adenocarcinoma. Int J Cancer. 2016 Oct 1; 139 (7):1626-31 Epub 2016 June 10
    View PubMed
  46. Yoon HH, Foster NR, Meyers JP, Steen PD, Visscher DW, Pillai R, Prow DM, Reynolds CM, Marchello BT, Mowat RB, Mattar BI, Erlichman C, Goetz MP. Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance). Ann Oncol. 2016 Feb; 27 (2):339-44 Epub 2015 Nov 16
    View PubMed
  47. Sinicrope FA, Mahoney MR, Yoon HH, Smyrk TC, Thibodeau SN, Goldberg RM, Nelson GD, Sargent DJ, Alberts SR, Alliance for Clinical Trials in Oncology. Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance). Clin Cancer Res. 2015 Dec 1; 21 (23):5294-304 Epub 2015 July 17
    View PubMed
  48. Yoon HH, Shi Q, Alberts SR, Goldberg RM, Thibodeau SN, Sargent DJ, Sinicrope FA, Alliance for Clinical Trials in Oncology. Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients. J Natl Cancer Inst. 2015 Oct; 107 (10) Epub 2015 July 09
    View PubMed
  49. Yoon HH, Tougeron D, Shi Q, Alberts SR, Mahoney MR, Nelson GD, Nair SG, Thibodeau SN, Goldberg RM, Sargent DJ, Sinicrope FA, Alliance for Clinical Trials in Oncology. KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). Clin Cancer Res. 2014 Jun 1; 20 (11):3033-43 Epub 2014 Mar 31
    View PubMed
  50. Yoon HH, Sukov WR, Shi Q, Sattler CA, Wiktor AE, Diasio RB, Wu TT, Jenkins RB, Sinicrope FA. HER-2/neu gene amplification in relation to expression of HER2 and HER3 proteins in patients with esophageal adenocarcinoma. Cancer. 2014 Feb 1; 120 (3):415-24 Epub 2013 Oct 21
    View PubMed
  51. Yoon HH. HER2 in Esophagogastric Adenocarcinoma. Int J Targeted Ther Cancer 2013.2013;2:(5)54-61.
  52. Yoon HH, Shi Q, Sukov WR, Lewis MA, Sattler CA, Wiktor AE, Wu TT, Diasio RB, Jenkins RB, Sinicrope FA. Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma. J Clin Oncol. 2012 Nov 10; 30 (32):3932-8 Epub 2012 Sept 17
    View PubMed
  53. Sinicrope FA, Foster NR, Yoon HH, Smyrk TC, Kim GP, Allegra CJ, Yothers G, Nikcevich DA, Sargent DJ. Association of obesity with DNA mismatch repair status and clinical outcome in patients with stage II or III colon carcinoma participating in NCCTG and NSABP adjuvant chemotherapy trials. J Clin Oncol. 2012 Feb 1; 30 (4):406-12 Epub 2011 Dec 27
    View PubMed
  54. Yoon HH, Shi Q, Sukov WR, Wiktor AE, Khan M, Sattler CA, Grothey A, Wu TT, Diasio RB, Jenkins RB, Sinicrope FA. Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clin Cancer Res. 2012 Jan 15; 18 (2):546-54
    View PubMed
  55. Yoon HH, Orrock JM, Foster NR, Sargent DJ, Smyrk TC, Sinicrope FA. Prognostic impact of FoxP3+ regulatory T cells in relation to CD8+ T lymphocyte density in human colon carcinomas. PLoS One. 2012; 7 (8):e42274 Epub 2012 Aug 06
    View PubMed
  56. Yoon HH, Lewis MA, Shi Q, Khan M, Cassivi SD, Diasio RB, Sinicrope FA. Prognostic impact of body mass index stratified by smoking status in patients with esophageal adenocarcinoma. J Clin Oncol. 2011 Dec 1; 29 (34):4561-7 Epub 2011 Oct 11
    View PubMed
  57. Yoon HH, Catalano P, Gibson MK, Skaar TC, Philips S, Montgomery EA, Hafez MJ, Powell M, Liu G, Forastiere AA, Benson AB, Kleinberg LR, Murphy KM. Genetic variation in radiation and platinum pathways predicts severe acute radiation toxicity in patients with esophageal adenocarcinoma treated with cisplatin-based preoperative radiochemotherapy: results from the Eastern Cooperative Oncology Group. Cancer Chemother Pharmacol. 2011 Oct; 68 (4):863-70 Epub 2011 Feb 01
    View PubMed
  58. Yoon HH, Catalano PJ, Murphy KM, Skaar TC, Philips S, Powell M, Montgomery EA, Hafez MJ, Offer SM, Liu G, Meltzer SJ, Wu X, Forastiere AA, Benson AB, Kleinberg LR, Gibson MK. Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology Group. BMC Cancer. 2011 May 17; 11:176
    View PubMed
  59. Yoon HH, Khan M, Shi Q, Cassivi SD, Wu TT, Quevedo JF, Burch PA, Sinicrope FA, Diasio RB. The prognostic value of clinical and pathologic factors in esophageal adenocarcinoma: a mayo cohort of 796 patients with extended follow-up after surgical resection. Mayo Clin Proc. 2010 Dec; 85 (12):1080-9
    View PubMed
  60. Yoon HH, Lowe VJ, Cassivi SD, Romero Y. The role of FDG-PET and staging laparoscopy in the management of patients with cancer of the esophagus or gastroesophageal junction. Gastroenterol Clin North Am. 2009 Mar; 38 (1):105-20, ix
    View PubMed
  61. Yoon HH, Gibson MK. Induction Chemotherapy Encyclopedia of Cancer 2008 (Living Reference Work Entry [updated 2015]; ed. Manfred Schwab); doi: 10.1007/978-3-642-27841-9_3040-2.2008;pp1-3.
  62. Yoon HH, Forastiere AA. Locally advanced esophageal adenocarcinoma: current standards and molecular predictors of outcome. Future Oncol. 2008 Jun; 4(3):413-25.
    View PubMed
  63. Yoon HH. Adapting to duty-hour limits--four years on. N Engl J Med. 2007 Jun 28; 356(26):2668-70.
    View PubMed
  64. Chung GG, Yoon HH, Zerkowski MP, Ghosh S, Thomas L, Harigopal M, Charette LA, Salem RR, Camp RL, Rimm DL, Burtness BA. Vascular endothelial growth factor, FLT-1, and FLK-1 analysis in a pancreatic cancer tissue microarray. Cancer. 2006 Apr 15; 106(8):1677-84.
    View PubMed
  65. Yoon HH, Kwon HL, Mattson RH, Spencer DD, Spencer SS. Long-term seizure outcome in patients initially seizure-free after resective epilepsy surgery. Neurology. 2003 Aug 26; 61(4):445-50.
    View PubMed
PST-20225353